Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BSX Stock Alerts

Boston Scientific (BSX) Competitors

Boston Scientific logo
$45.29 +0.31 (+0.69%)
As of 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

BSX vs. ALGN, HQY, MMSI, AMN, and DVA

Should you buy Boston Scientific stock or one of its competitors? Boston Scientific's main competitors and comparable companies include Align Technology (ALGN), HealthEquity (HQY), Merit Medical Systems (MMSI), AMN Healthcare Services (AMN), and DaVita (DVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Boston Scientific compare to Align Technology?

Boston Scientific (NYSE:BSX) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Boston Scientific has a net margin of 17.50% compared to Align Technology's net margin of 9.99%. Boston Scientific's return on equity of 19.28% beat Align Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific17.50% 19.28% 10.89%
Align Technology 9.99%15.86%10.32%

Boston Scientific has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Boston Scientific has higher revenue and earnings than Align Technology. Boston Scientific is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.27$2.90B$2.4718.34
Align Technology$4.14B2.64$410.35M$5.7526.55

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 88.4% of Align Technology shares are held by institutional investors. 0.3% of Boston Scientific shares are held by insiders. Comparatively, 0.8% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Boston Scientific currently has a consensus price target of $71.46, indicating a potential upside of 57.78%. Align Technology has a consensus price target of $206.36, indicating a potential upside of 35.15%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Boston Scientific is more favorable than Align Technology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71
Align Technology
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, Boston Scientific had 28 more articles in the media than Align Technology. MarketBeat recorded 36 mentions for Boston Scientific and 8 mentions for Align Technology. Align Technology's average media sentiment score of 1.47 beat Boston Scientific's score of 0.51 indicating that Align Technology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive
Align Technology
6 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Boston Scientific beats Align Technology on 11 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to HealthEquity?

Boston Scientific (NYSE:BSX) and HealthEquity (NASDAQ:HQY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Boston Scientific has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, HealthEquity has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Boston Scientific currently has a consensus target price of $71.46, suggesting a potential upside of 57.78%. HealthEquity has a consensus target price of $111.87, suggesting a potential upside of 20.51%. Given Boston Scientific's higher probable upside, analysts plainly believe Boston Scientific is more favorable than HealthEquity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71
HealthEquity
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.6% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Boston Scientific has a net margin of 17.50% compared to HealthEquity's net margin of 17.36%. Boston Scientific's return on equity of 19.28% beat HealthEquity's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific17.50% 19.28% 10.89%
HealthEquity 17.36%15.33%9.51%

In the previous week, Boston Scientific had 31 more articles in the media than HealthEquity. MarketBeat recorded 36 mentions for Boston Scientific and 5 mentions for HealthEquity. HealthEquity's average media sentiment score of 0.92 beat Boston Scientific's score of 0.51 indicating that HealthEquity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive
HealthEquity
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific has higher revenue and earnings than HealthEquity. Boston Scientific is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.27$2.90B$2.4718.34
HealthEquity$1.36B5.64$215.20M$2.7733.51

Summary

Boston Scientific beats HealthEquity on 9 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Boston Scientific (NYSE:BSX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Boston Scientific had 31 more articles in the media than Merit Medical Systems. MarketBeat recorded 36 mentions for Boston Scientific and 5 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.19 beat Boston Scientific's score of 0.51 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merit Medical Systems
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive

Boston Scientific has higher revenue and earnings than Merit Medical Systems. Boston Scientific is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$1.52B3.42$128.49M$2.4235.91
Boston Scientific$20.07B3.27$2.90B$2.4718.34

Merit Medical Systems currently has a consensus target price of $100.00, suggesting a potential upside of 15.07%. Boston Scientific has a consensus target price of $71.46, suggesting a potential upside of 57.78%. Given Boston Scientific's higher possible upside, analysts plainly believe Boston Scientific is more favorable than Merit Medical Systems.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71

Boston Scientific has a net margin of 17.50% compared to Merit Medical Systems' net margin of 9.22%. Boston Scientific's return on equity of 19.28% beat Merit Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Merit Medical Systems9.22% 13.75% 8.10%
Boston Scientific 17.50%19.28%10.89%

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by company insiders. Comparatively, 0.3% of Boston Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Merit Medical Systems has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Summary

Boston Scientific beats Merit Medical Systems on 10 of the 17 factors compared between the two stocks.

How does Boston Scientific compare to AMN Healthcare Services?

Boston Scientific (NYSE:BSX) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Boston Scientific has a net margin of 17.50% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Boston Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific17.50% 19.28% 10.89%
AMN Healthcare Services 3.06%19.92%5.93%

Boston Scientific has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$20.07B3.27$2.90B$2.4718.34
AMN Healthcare Services$3.43B0.39-$95.70M$2.6812.79

Boston Scientific presently has a consensus target price of $71.46, suggesting a potential upside of 57.78%. AMN Healthcare Services has a consensus target price of $31.43, suggesting a potential downside of 8.33%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.3% of Boston Scientific shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Boston Scientific had 29 more articles in the media than AMN Healthcare Services. MarketBeat recorded 36 mentions for Boston Scientific and 7 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.73 beat Boston Scientific's score of 0.51 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive
AMN Healthcare Services
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Summary

Boston Scientific beats AMN Healthcare Services on 11 of the 16 factors compared between the two stocks.

How does Boston Scientific compare to DaVita?

DaVita (NYSE:DVA) and Boston Scientific (NYSE:BSX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Boston Scientific has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$14.01B0.84$746.80M$12.2215.03
Boston Scientific$20.07B3.27$2.90B$2.4718.34

In the previous week, Boston Scientific had 31 more articles in the media than DaVita. MarketBeat recorded 36 mentions for Boston Scientific and 5 mentions for DaVita. DaVita's average media sentiment score of 0.61 beat Boston Scientific's score of 0.51 indicating that DaVita is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DaVita
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
14 Very Positive mention(s)
7 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Positive

90.1% of DaVita shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 1.9% of DaVita shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DaVita presently has a consensus price target of $221.75, indicating a potential upside of 20.77%. Boston Scientific has a consensus price target of $71.46, indicating a potential upside of 57.78%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than DaVita.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DaVita
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Boston Scientific
2 Sell rating(s)
5 Hold rating(s)
24 Buy rating(s)
0 Strong Buy rating(s)
2.71

DaVita has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Boston Scientific has a net margin of 17.50% compared to DaVita's net margin of 6.05%. Boston Scientific's return on equity of 19.28% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
DaVita6.05% -217.63% 5.07%
Boston Scientific 17.50%19.28%10.89%

Summary

Boston Scientific beats DaVita on 11 of the 16 factors compared between the two stocks.

Get Boston Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSX vs. The Competition

Export
MetricBoston ScientificHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$65.54B$5.45B$7.15B$23.32B
Dividend YieldN/A1.76%2.54%3.73%
P/E Ratio18.3125.01271.9028.78
Price / Sales3.2786.67697.5496.54
Price / Cash11.8532.9577.0733.53
Price / Book2.756.3210.814.76
Net Income$2.90B$150.94M$3.48B$1.07B
7 Day Performance-6.42%-1.97%-0.91%-0.76%
1 Month Performance-8.23%-0.70%2.70%-2.10%
1 Year Performance-58.12%8.32%21.40%11.88%

Boston Scientific Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSX
Boston Scientific
4.7112 of 5 stars		$45.29
+0.7%		$71.46
+57.8%		-58.4%$65.54B$20.07B18.3159,000
ALGN
Align Technology
4.4033 of 5 stars		$159.79
+1.4%		$206.36
+29.1%		+12.2%$11.44B$4.03B27.7920,290
HQY
HealthEquity
4.5217 of 5 stars		$96.54
+0.2%		$111.87
+15.9%		+0.3%$7.98B$1.31B34.852,814
MMSI
Merit Medical Systems
3.8954 of 5 stars		$90.66
+0.2%		$100.00
+10.3%		-5.4%$5.41B$1.52B37.467,500
AMN
AMN Healthcare Services
2.5154 of 5 stars		$34.23
-1.1%		$31.43
-8.2%		+61.0%$1.33B$3.43B12.772,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BSX) was last updated on 9/9/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel